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AbstrAct
background Anticipatory prescribing (AP) of 
injectable medications in advance of clinical 
need is established practice in community end- 
of- life care. Changes to prescribing guidelines 
and practice have been reported during the 
COVID-19 pandemic.
Aims and objectives To investigate UK and 
Ireland clinicians’ experiences concerning 
changes in AP during the COVID-19 pandemic 
and their recommendations for change.
Methods Online survey of participants at 
previous AP national workshops, members 
of the Association for Palliative Medicine of 
Great Britain and Ireland and other professional 
organisations, with snowball sampling.
results Two hundred and sixty- one replies were 
received between 9 and 19 April 2020 from 
clinicians in community, hospice and hospital 
settings across all areas of the UK and Ireland. 
Changes to AP local guidance and practice were 
reported: route of administration (47%), drugs 
prescribed (38%), total quantities prescribed 
(35%), doses and ranges (29%). Concerns over 
shortages of nurses and doctors to administer 
subcutaneous injections led 37% to consider 
drug administration by family or social caregivers, 
often by buccal, sublingual and transdermal 
routes. Clinical contact and patient assessment 
were more often remote via telephone or 
video (63%). Recommendations for regulatory 
changes to permit drug repurposing and easier 
community access were made.
conclusions The challenges of the COVID-19 
pandemic for UK community palliative care has 
stimulated rapid innovation in AP. The extent to 
which these are implemented and their clinical 
efficacy need further examination.
IntroductIon
Anticipatory prescribing (AP) is the 
prescribing and dispensing of injectable 
medications in advance of clinical need, 
for visiting nurses or doctors to give as 
required if symptoms (pain, nausea and 
vomiting, agitation and respiratory tract 
secretions and breathlessness) arise in 
the final days of life.1–3 AP may optimise 
symptom control for deaths in the commu-
nity1 4–8: it is well established and widely 
recommended in the UK, New Zealand 
and Australia,1–3 9–12 and less commonly 
in the USA, Singapore and Norway.13–16
The number of people dying in care 
homes and at home has risen dramati-
cally during the COVID-19 pandemic in 
the UK and in many other countries.17 18 
AP guidance and practice has changed 
in response.1 5–7 19 There is alarm about 
depleted drug stocks and that nurses and 
doctors may not be readily available to 
give injections.5 20 Recent UK guidance 
proposed both family caregiver adminis-
tration and use of different drug formu-
lations via the buccal, rectal or sublingual 
routes along with traditional subcuta-
neous injections.5–7 21
The evidence base for current AP prac-
tice is sparse,2 3 9 16 22–26 even more so for 
the buccal or sublingual routes, which 
are based primarily on professional expe-
rience and within paediatric palliative 
care.13–15 27
Family caregivers have rarely admin-
istered AP medications in the UK.27–29 
Australian experience suggests family 
caregivers appreciate being able to 
provide symptom relief: some struggle 
with the responsibility10 30 31 and/or 
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worry it is a form of euthanasia.10 Media concerns 
have focused on family caregivers having a great 
responsibility but without adequate training or 
oversight.20
To support practitioners and policy- makers, we 
surveyed UK/Ireland professionals and investigated 
how AP practice has changed in response to revised 
national guidance and local demands during the 
COVID-19 pandemic.
Aims and research questions
With regard to AP practice during the COVID-19 
pandemic, what do practitioners report in relation to
1. Changes in drug prescription?
2. Changes in drug administration?
3. Changes in support structures for AP?
4. Suggestions for further changes?
Methods
An online survey (see online supplementary appendix) 
was developed in Survey Monkey based on the liter-
ature, our own clinical experience and SB’s recent 
correspondence with palliative care and primary care 
colleagues across the UK. The study was reviewed 
by the University of Cambridge Psychology Research 
Ethics Committee (PRE.2019.013)
After a local pilot, an email with the survey link was 
sent between 8 and 13 April 2020 to delegates who 
attended AP workshops in 2019 for doctors, nurses and 
pharmacists in palliative and primary care; members of 
the Association for Palliative Medicine of Great Britain 
and Ireland, the National Institute for Health and Social 
Care Excellence Medicines Associate Programme and 
Resilient GP Facebook Group, UK Queen’s Nursing 
Institute. Colleagues were encouraged to forward the 
survey link to interested colleagues, seeking a snowball 
sample of practitioners.32
All fields were mandatory and responses were anon-
ymous unless respondents supplied their name and 
email address in the optional final field to indicate 
interest in a follow- up telephone interview.
Questions 1–4 sought demographic data concerning 
respondents’ geographical areas of work, professional 
roles, clinical work settings and involvement in AP. 
Question 5 addressed changes in AP practice (if any) 
during the COVID-19 pandemic. These included 
drug types prescribed, total quantities dispensed, drug 
doses/ranges, drugs and support documents in home/
care home, route of administration especially sublin-
gual/buccal, persons administering AP drugs (especially 
family or social care colleagues), advice and support for 
non- clinical administration, phone or video support, 
prescribing in non- COVID- related illness and syringe 
driver use. Reasons for any changes in practice were 
invited in free text. Question 6 invited comments and 
suggestions for changes in practice, policy and legisla-
tion to optimise AP.
data analysis
The Checklist for Reporting Results of Internet E- Sur-
veys was followed.33 Descriptive statistics were used for 
demographic and categorical response data. For free- 
text replies to Questions 5 and 6, BA, BB, IW and SB 
developed themes inductively from the data, allocating 
responses to themes developed for each subquestion.34 
These are presented with illustrative quotations.
results
respondents
Two hundred and sixty- one replies were received 
between 9 and 19 April 2020, from palliative medicine 
consultants (CONS 97, 37%), general practitioners 
(GP 63, 24%), palliative care specialist nurses (CNS 
31, 12%), general community nurses (8, 7%), palli-
ative medicine trainees (15, 6%), other doctors (12, 
5%), pharmacists (5, 2%), other nurses (4, 2%) and 
other professional group (16, 6%). The geographical 
distribution of respondents is shown in figure 1.
Clinical work settings were community specialist 
palliative care (144, 55%), hospice inpatient unit (104, 
40%), community primary care (96, 37%), hospital 
(87, 33%), care home (29, 11%) and other settings (7, 
3%). All respondents were working clinically. Partic-
ipants’ involvement in the AP process were decision 
to prescribe (239, 92%), prescribing (225, 86%), 
dispensing (12, 5%), monitoring before drug admin-
istration (99, 38%), medication administration (53, 
20%) and medication disposal after death (13, 5%).
changes in AP practice
Respondents’ reports of any changes in AP practice in 
their area, with examples from thematic analysis of the 
explanatory free text, are listed in table 1.
Marked changes in AP were reported by about one- 
third in most domains. Changes in route of admin-
istration (47%) and drugs prescribed (38%) were 
associated with consideration of buccal, sublingual 
and transdermal routes and avoidance of subcuta-
neous injections. These related to possible adminis-
tration by family or social caregivers (37%) and drug 
availability. Changes in quantities prescribed (35%) 
and doses/ranges (29%) reflected the reported needs 
of some dying with COVID-19 for higher doses and 
more frequent administration to control symptoms 
than previously (and to protect limited medication 
supplies). Changes were under way to facilitate drug 
delivery and relevant paperwork to the home (36%).
At the same time, clinical contact and patient assess-
ment were changing to telephone or video rather than 
in person (63%). Telephone advice was more available 
(49%). Changes in prescribing for non- COVID-19 
terminal illness (24%) reflected moves towards non- 
injectable routes and concern that they might develop 
COVID-19 and associated severe agitation. Planned 
reductions in syringe driver use (30%) reflected 
perceptions that the COVID-19 terminal phase is brief 
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Figure 1 Distribution of responders across Great Britain and Ireland.
and best managed with ‘as needed’ individual doses 
and that both district nurses and syringe drivers might 
be in short supply.
Practitioners’ comments and suggestions for change
The dominant themes were calls for three changes in 
pharmaceutical legislation.
Permit repurposing of prescribed AP drugs in care homes
Allowing care homes to re- use AP medications when 
the patient has died and the drugs have not been used. 
Such a waste of meds. #209 CONS
COVID outbreak in nursing home we care for. 
Would be very useful if could re- use Anticipatory 
subcutaneous medications and also if the nursing home 
could hold a small supply. #227 GP
Enable wider ready access to drugs in the community
Nursing homes have asked for spare sets of anticipa-
tory medications should patients unexpectedly become 
unwell, but this is not within the law. #142 GP
It would be really helpful to have a centralised stock 
of AP drugs (maybe with community nursing teams) 
so that each patient just has what they need dispensed 
when they need it. #170 GP
Having access 24 hours for anticipatory meds: 
prescription and meds in key localities to enable rapid 
response and symptom control. #119 CNS
Permit recycling of drugs returned to pharmacies
Enable unused vials to be taken back to pharmacy and 
reused. Fear of waste and cost are factors that limit the 
amount of AP in the community. #245 CONS
This is our opportunity to secure legislative change 
for the establishment of centralised supplies, the ability 
for clinical staff to have sensible safe boxes and for the 
return of safe, unused drugs to pharmacies … This is 
a known and appalling waste that must stop now and 
be permanent. There has never been a cogent justifica-
tion. #100 CONS
dIscussIon
This study revealed rapid change in AP practice is 
under consideration in many areas of the UK/Ireland: 
increased use of alternative routes, changes in drugs 
prescribed to address stock shortages, new routes of 
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Table 1 AP practice changes during COVID-19
Changes to Yes No Unsure Illustrative comment examples
Which drugs are prescribed? 98 (38%) 146 (56%) 17 (7%)  ► More off- licence drug use #83 CONS.
 ► Including non- injectables, for example, buccal midazolam in case 
no nurse can attend #14 CONS.
 ► Changing with availability: hyoscine patch for glycopyrronium 
#253 CNS.
The quantities of drugs prescribed? 90 (35%) 137 (53%) 34 (13%)  ► Prescribing smaller quantities to preserve stocks #51 CONS.
 ► Larger doses for ARDS: may need repeated sooner #127 TRAIN.
 ► Continuing normal practice #217 DOC.
Drug doses/dose ranges prescribed? 75 (29%) 163 (63%) 23 (9%)  ► Higher starting doses for distress, especially levomepromazine 
#241 CONS.
 ► Up to 1- hourly if dyspnoea or distress persist #102 CONS
 ► Quicker escalation to larger doses for some #99 GP.
 ► Wider ranges and more prescribed to cover every eventuality 
#83 CONS.
Arrangements for drugs and supporting 
documents to be in the home/care home?
96 (36%) 135 (52%) 31 (12%)  ► Authorisation sheet electronic #240 GP
 ► ‘Grab bags' with anticipatory meds available in emergency 
department #248 CONS.
 ► Stores with army to deliver: 'just in case' changed to 'just in 
time' #134 CONS.
Route of administration, especially the 
sublingual/buccal route?
122 (47%) 124 (48%) 15 (6%)  ► Oral/buccal routes give patients/relative more control without 
HCP #84 CONS.
 ► Subcutaneous route first, buccal/transdermal use if availability of 
SC drugs affected #64 CNS.
 ► Lorazepam, hyoscine and fentanyl patches alternatives if SC 
meds not available #5 CONS.
Person administering AP drugs, especially 
family/informal carers or social care 
colleagues?
97 (37%) 136 (52%) 28 (11%)  ► Family offered chance to learn if they want to #217 DOC.
 ► Care home staff rather than district nurse after phone advice 
#213 GP.
 ► Already have carer administering SC policy #244 CONS.
Telephone or other advice and support 
for AP, including family/social care 
administration?
127 (49%) 113 (43%) 21 (8%)  ► Advice line 17:00–21:00. Increased our cover on weekend and 
Bank Holiday #10 CNS.
 ► Decision for AP made on FaceTime #46 OTHER.
 ► Much more remote working now; complete change in practice 
#150 GP.
The use of phone or video to support AP 
practice?
165 (63%) 78 (30%) 18 (7%)  ► Care now via telephone or video including AP advice #131 DOC.
 ► Reduces risk of transmission and aids completion of forms when 
patient dies #176 GP.
 ► Video review to make decision patient is dying; may need visit in 
person #240 GP.
The prescribing of AP medications for 
patients with non- COVID- related illness?
63 (24%) 181 (69%) 17 (7%)  ► Any patient could develop COVID, anticipating higher likelihood 
of agitation #71 TRAIN.
 ► Consider non injectables for non- complex #22 CONS.
 ► Preparing for how to cope without syringe drivers #150 GP.
The use of syringe drivers? 79 (30%) 165 (63%) 17 (7%)  ► Few patients with COVID need syringe pumps as they die very 
quickly #240 GP.
 ► Most dying patients with COVID easily managed by stat doses 
#103 CONS.
 ► Patches due to equipment and DN resources #39 TRAIN.
AP, anticipatory prescribing; CNS, palliative care specialist nurse; CONS, palliative medicine consultant; DN, district nurse; DOC, doctor; GP, general 
practitioner; HCP, health care professional; OTHER, other professional group; TRAIN, palliative medicine trainee.
administration, family caregiver administration; later 
prescribing of AP drugs and smaller quantities. There 
were calls to new pharmaceutical regulations to permit 
repurposing of AP medications in care homes, wider 
community drug access and recycling unused medi-
cations returned to pharmacies. Reflecting broader 
changes in community end- of- life- care during the 
pandemic, more end- of- life care in general and AP in 
particular is undertaken remotely and electronically, 
with increased 24 hours availability. These changes 
will potentially significantly affect care during the 
pandemic and in the future.
The main strengths of this study were the large 
number of responses, the broad distribution of replies 
from across the UK and Ireland and the contempora-
neous data. Anonymity encouraged candid responses. 
It is not possible to calculate a response rate due to the 
snowball sampling.
Major changes are under way in routes of AP drug 
administration; community adult end- of- life care prac-
tice is increasingly accepting the buccal and sublingual 
routes. Robust evidence is urgently needed about their 
pharmacokinetics to develop evidence- based guide-
lines on suitable drugs, preparations and doses which 
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is currently based largely on clinical experience in 
paediatric palliative care. While transdermal adminis-
tration is well established, it lacks the flexibility and 
rapidity of relief when symptoms are unstable in the 
dying.27 This is particularly important for those dying 
from COVID-19 in whom there is a need for higher 
drug doses and more frequent administration for effec-
tive symptom control.
Many areas are adopting proposals in national poli-
cies to consider caregiver drug administration.35 This 
is a big ask for family caregivers with significant risks 
for their psychological welfare. They may feel pres-
sure to undertake clinical tasks; responsibility for 
medications heightens anxieties during an already 
emotional time.10 36 Nurses often worry about overse-
dating patients or accelerating death when they give 
end- of- life medications.3 23 Should a patient die shortly 
after family caregivers give a medication, they may 
have even greater concerns.10 37 Clinicians must be 
careful whom they approach to undertake these tasks, 
discuss alternative care options and ensure appropriate 
training and support is available for willing family 
caregivers.6 19 28 30 31 After death, family caregivers 
confront these worries while being isolated in their 
grief during the pandemic.19
Many palliative care services have responded to 
the pandemic with extended availability of telephone 
advice for clinical and social care colleagues, often 
now including patients and family members. These are 
welcome developments. The move of much community 
palliative care to remote video or telephone consulta-
tions is understandable due to the need to avoid infec-
tion risk to patient, family and clinician. However, this 
change risks impairing the quality of communication 
and clinical assessments involved. Video diagnosis of 
the dying phase and AP decisions, reported by partic-
ipants, require remote consultation skills that may 
be more familiar to general practitioners than some 
working in palliative care services.
Pharmaceutical regulations and policies pertaining 
to AP in care homes arise from legitimate needs to 
protect residents from drug errors, particularly with 
controlled drugs like morphine and midazolam.38 39 
The presence of suitable medications already in the 
homes, prescribed for one resident but then urgently 
needed for another, is frustrating for care home staff 
and visiting clinicians, as until recently they have 
been unable to repurpose drugs. Recent UK guidance, 
issued on 28 April 2020, now permits repurposing in 
care homes and hospices: this welcome development, 
called for by many participants, was introduced after 
data collection was complete.40 The related regula-
tions requiring destruction of medications after death 
and on return to a pharmacy is as yet unresolved.39 
These tensions are not new but more acute during the 
pandemic when many care home residents are at risk 
of dying from COVID-19 and drugs may be in short 
supply.5 A focus on preserving limited drug stocks may 
delay AP until an individual is close to the end of their 
life, but risks undermining ready drug availability, 
which is the essence of AP.
Respondents reported that some dying from 
COVID-19 have a relatively brief dying phase requiring 
larger than usual drug doses. This makes current guid-
ance to prescribe drugs in small amounts and close to 
anticipated death problematic. Community clinicians 
are conflicted. Wider and more ready community drug 
access might ease this difficulty but presents legislative 
and logistical challenges.19
conclusIons
The COVID-19 pandemic is a challenge to commu-
nity palliative care. It creates opportunities to inno-
vate rapidly and learn from paediatric palliative care. 
Given the risk from face- to- face consultations and 
visits for drug administration, care is now more virtual 
and remote, with greater dependence on family care-
givers to provide care and administer drugs, often via 
non- injectable routes. These changes are occurring at 
pace: it remains to be seen how widely they are imple-
mented, how effective they are and how much they 
will persist after the pandemic. We would welcome 
collaborations with colleagues across the world to 
address these important questions.
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